Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Adverse Business Impact

Medplus Health Services Adverse Business Impact

The FDA suspended the drug license of a Medplus subsidiary's store in Prabhadevi, Maharashtra for 15 days. The financial impact is estimated at Rs 14.25 lakhs.

Key figures
Value₹0.14 Cr
Order fromFood and Drug Administration, Mumbai, Maharashtra
Execution period15 days
Source

NSE filing, NSE: MEDPLUS. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Medplus Health Services Ltd: key numbers

Share price
₹609.40
Market cap
₹7,321 Cr
Revenue (annual)
₹6,892 Cr
Net profit (annual)
₹219.7 Cr
P/E (TTM)
34.7×Sector 52.0×
Promoter holding
40.19%+0.00% QoQ
FII holding
12.58%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Medplus Health Services Ltd

All →

Other adverse business impact announcements

All →